CytomX Therapeutics

CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody™ therapeutics. Our novel Probody Platform allows us to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This unique ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, we are advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying our technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies. The Probody Platform has attracted strategic partnerships with leading pharmaceutical companies and research institutions, including AbbVie™, Bristol-Myers Squibb™, Pfizer™, ImmunoGen™ and MD Anderson Cancer Center™. Through these and other collaborations, we broaden the reach of our technology.
South San Francisco, US
Size (employees)
78 (est)+20%
CytomX Therapeutics is headquartered in South San Francisco, US

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
100 343 Oyster Point Blvd

CytomX Therapeutics Metrics

CytomX Therapeutics Financial Metrics

Revenue (2016)

$15 m

Net income (2016)

($58.9 m)

Market capitalization (21-Mar-2017)

$693.8 m

Closing share price (21-Mar-2017)

CytomX Therapeutics's current market capitalization is $693.8 m.
CytomX Therapeutics's revenue was reported to be $15 m in FY, 2016
FY, 2016


$15 m

Net Income

($58.9 m)

CytomX Therapeutics Market Value History

CytomX Therapeutics Online Presence

CytomX Therapeutics Company Life

You may also be interested in